tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Astellas Pharma Continues Performance-linked Stock Schemes for Executives
Company AnnouncementsAstellas Pharma Continues Performance-linked Stock Schemes for Executives
4d ago
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
PremiumCompany Announcements
Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
4d ago
Astellas Pharma Announces Changes to Board of Directors
PremiumCompany Announcements
Astellas Pharma Announces Changes to Board of Directors
12d ago
Astellas Pharma Reports Record Revenue and Growth
PremiumCompany Announcements
Astellas Pharma Reports Record Revenue and Growth
20d ago
Astellas Pharma Reports Higher Than Expected Financial Results
PremiumCompany Announcements
Astellas Pharma Reports Higher Than Expected Financial Results
24d ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
26d ago
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
Premium
Company Announcements
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
3M ago
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
Premium
Company Announcements
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
3M ago
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
PremiumCompany Announcements
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
3M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
PremiumCompany Announcements
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
4M ago
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
PremiumCompany Announcements
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
4M ago
Astellas Faces FDA Setback on IZERVAY Application
PremiumCompany AnnouncementsAstellas Faces FDA Setback on IZERVAY Application
6M ago
Astellas Pharma Faces Currency Losses in FY2024
Premium
Company Announcements
Astellas Pharma Faces Currency Losses in FY2024
7M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
7M ago
Astellas Pharma Withdraws EU Application for Key Drug
PremiumCompany Announcements
Astellas Pharma Withdraws EU Application for Key Drug
7M ago
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
PremiumCompany Announcements
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
7M ago
Astellas’ New Cancer Therapy Gains Japan Approval
PremiumCompany Announcements
Astellas’ New Cancer Therapy Gains Japan Approval
8M ago
Astellas Wins EU Approval for Advanced Cancer Drug
PremiumCompany Announcements
Astellas Wins EU Approval for Advanced Cancer Drug
8M ago
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
PremiumThe FlyBicycle says 45% of patients respond to bladder cancer drug, EN reports
8M ago
MRK
PFE
Astellas Pharma Prices New Unsecured Bonds
Premium
Company Announcements
Astellas Pharma Prices New Unsecured Bonds
9M ago
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
Premium
Company Announcements
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >